The KLC1 antibody targets Kinesin Light Chain 1 (KLC1), a critical component of the kinesin-1 motor protein complex. Kinesins are microtubule-dependent molecular motors responsible for intracellular transport, facilitating the movement of organelles, vesicles, and macromolecules toward the cell periphery. KLC1 binds to the kinesin heavy chain (KHC) to form the kinesin-1 heterotetramer, which plays a key role in anterograde transport, particularly in neurons, where it supports axonal trafficking. KLC1 also regulates cargo binding through its tetratricopeptide repeat (TPR) domains, enabling interactions with diverse cargoes, including mitochondria, lysosomes, and mRNA-protein complexes.
KLC1 antibodies are widely used in research to study intracellular transport mechanisms, neuronal development, and diseases linked to kinesin dysfunction, such as neurodegenerative disorders (e.g., Alzheimer’s and Charcot-Marie-Tooth disease) and cancer. Dysregulation of KLC1 has been implicated in impaired axonal transport, altered cell division, and tumor metastasis. These antibodies enable detection of KLC1 expression levels, subcellular localization (via immunofluorescence or immunohistochemistry), and protein interactions (via co-immunoprecipitation). Commercial KLC1 antibodies are typically validated in applications like Western blotting, flow cytometry, and confocal microscopy, aiding in both basic and translational research.